iCAD, Inc.
iCAD, Inc. (ICAD) Stock Competitors & Peer Comparison
See (ICAD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ICAD | $3.87 | +3.75% | 106.3M | -20.37 | -$0.19 | N/A |
| ABT | $107.19 | +0.00% | 183.4B | 28.37 | $3.72 | +2.26% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $339.76 | +0.00% | 128.5B | 39.93 | $8.41 | +1.01% |
| MDT | $86.87 | +0.00% | 110.7B | 24.08 | $3.58 | +3.29% |
| BSX | $69.89 | +0.00% | 103.1B | 35.83 | $1.94 | N/A |
| EW | $82.46 | +0.00% | 47.9B | 45.60 | $1.81 | N/A |
| BRKRP | $273.45 | +0.39% | 40.8B | N/A | N/A | +0.60% |
| DXCM | $67.27 | +0.00% | 26.1B | 32.03 | $2.09 | N/A |
| PHG | $26.86 | +0.00% | 25.2B | 24.54 | $1.07 | +3.38% |
Stock Comparison
ICAD vs ABT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ABT has a market cap of 183.4B. Regarding current trading prices, ICAD is priced at $3.87, while ABT trades at $107.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ABT's P/E ratio is 28.37. In terms of profitability, ICAD's ROE is -0.12%, compared to ABT's ROE of +0.13%. Regarding short-term risk, ICAD is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ABT's competition here
ICAD vs BSX-PA Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ICAD is priced at $3.87, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ICAD's ROE is -0.12%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, ICAD is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BSX-PA's competition here
ICAD vs SYK Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SYK has a market cap of 128.5B. Regarding current trading prices, ICAD is priced at $3.87, while SYK trades at $339.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SYK's P/E ratio is 39.93. In terms of profitability, ICAD's ROE is -0.12%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SYK's competition here
ICAD vs MDT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MDT has a market cap of 110.7B. Regarding current trading prices, ICAD is priced at $3.87, while MDT trades at $86.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MDT's P/E ratio is 24.08. In terms of profitability, ICAD's ROE is -0.12%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check MDT's competition here
ICAD vs BSX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSX has a market cap of 103.1B. Regarding current trading prices, ICAD is priced at $3.87, while BSX trades at $69.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSX's P/E ratio is 35.83. In terms of profitability, ICAD's ROE is -0.12%, compared to BSX's ROE of +0.13%. Regarding short-term risk, ICAD is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BSX's competition here
ICAD vs EW Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, EW has a market cap of 47.9B. Regarding current trading prices, ICAD is priced at $3.87, while EW trades at $82.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas EW's P/E ratio is 45.60. In terms of profitability, ICAD's ROE is -0.12%, compared to EW's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check EW's competition here
ICAD vs BRKRP Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BRKRP has a market cap of 40.8B. Regarding current trading prices, ICAD is priced at $3.87, while BRKRP trades at $273.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ICAD's ROE is -0.12%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, ICAD and BRKRP have similar daily volatility (0.00).Check BRKRP's competition here
ICAD vs DXCM Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, DXCM has a market cap of 26.1B. Regarding current trading prices, ICAD is priced at $3.87, while DXCM trades at $67.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas DXCM's P/E ratio is 32.03. In terms of profitability, ICAD's ROE is -0.12%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, ICAD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check DXCM's competition here
ICAD vs PHG Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PHG has a market cap of 25.2B. Regarding current trading prices, ICAD is priced at $3.87, while PHG trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PHG's P/E ratio is 24.54. In terms of profitability, ICAD's ROE is -0.12%, compared to PHG's ROE of +0.08%. Regarding short-term risk, ICAD is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PHG's competition here
ICAD vs STE Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, STE has a market cap of 21.6B. Regarding current trading prices, ICAD is priced at $3.87, while STE trades at $217.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas STE's P/E ratio is 30.45. In terms of profitability, ICAD's ROE is -0.12%, compared to STE's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check STE's competition here
ICAD vs ZBH Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ZBH has a market cap of 17.4B. Regarding current trading prices, ICAD is priced at $3.87, while ZBH trades at $89.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ZBH's P/E ratio is 24.76. In terms of profitability, ICAD's ROE is -0.12%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ICAD is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ZBH's competition here
ICAD vs ABMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ICAD is priced at $3.87, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ICAD's ROE is -0.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ABMD's competition here
ICAD vs PODD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PODD has a market cap of 16B. Regarding current trading prices, ICAD is priced at $3.87, while PODD trades at $228.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PODD's P/E ratio is 65.26. In terms of profitability, ICAD's ROE is -0.12%, compared to PODD's ROE of +0.17%. Regarding short-term risk, ICAD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PODD's competition here
ICAD vs SNN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SNN has a market cap of 13.6B. Regarding current trading prices, ICAD is priced at $3.87, while SNN trades at $32.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SNN's P/E ratio is 22.33. In terms of profitability, ICAD's ROE is -0.12%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ICAD is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SNN's competition here
ICAD vs PEN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PEN has a market cap of 13.2B. Regarding current trading prices, ICAD is priced at $3.87, while PEN trades at $337.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PEN's P/E ratio is 74.20. In terms of profitability, ICAD's ROE is -0.12%, compared to PEN's ROE of +0.13%. Regarding short-term risk, ICAD is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PEN's competition here
ICAD vs SWAV Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ICAD is priced at $3.87, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ICAD's ROE is -0.12%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ICAD is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SWAV's competition here
ICAD vs ALGN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ICAD is priced at $3.87, while ALGN trades at $176.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ALGN's P/E ratio is 30.59. In terms of profitability, ICAD's ROE is -0.12%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ALGN's competition here
ICAD vs GMED Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, GMED has a market cap of 11.7B. Regarding current trading prices, ICAD is priced at $3.87, while GMED trades at $86.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas GMED's P/E ratio is 22.01. In terms of profitability, ICAD's ROE is -0.12%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ICAD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check GMED's competition here
ICAD vs BIO Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BIO has a market cap of 7.1B. Regarding current trading prices, ICAD is priced at $3.87, while BIO trades at $265.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BIO's P/E ratio is 9.49. In terms of profitability, ICAD's ROE is -0.12%, compared to BIO's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BIO's competition here
ICAD vs BIO-B Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, ICAD is priced at $3.87, while BIO-B trades at $268.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BIO-B's P/E ratio is 9.48. In terms of profitability, ICAD's ROE is -0.12%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, ICAD and BIO-B have similar daily volatility (0.00).Check BIO-B's competition here
ICAD vs GKOS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, ICAD is priced at $3.87, while GKOS trades at $102.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas GKOS's P/E ratio is -30.76. In terms of profitability, ICAD's ROE is -0.12%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, ICAD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check GKOS's competition here
ICAD vs BRKR Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BRKR has a market cap of 5.1B. Regarding current trading prices, ICAD is priced at $3.87, while BRKR trades at $33.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BRKR's P/E ratio is -222.20. In terms of profitability, ICAD's ROE is -0.12%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, ICAD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BRKR's competition here
ICAD vs NARI Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ICAD is priced at $3.87, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NARI's P/E ratio is -59.24. In terms of profitability, ICAD's ROE is -0.12%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ICAD is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check NARI's competition here
ICAD vs TMDX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, ICAD is priced at $3.87, while TMDX trades at $113.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TMDX's P/E ratio is 23.39. In terms of profitability, ICAD's ROE is -0.12%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, ICAD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check TMDX's competition here
ICAD vs IRTC Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ICAD is priced at $3.87, while IRTC trades at $117.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IRTC's P/E ratio is -84.26. In terms of profitability, ICAD's ROE is -0.12%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, ICAD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check IRTC's competition here
ICAD vs AXNX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ICAD is priced at $3.87, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ICAD's ROE is -0.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ICAD and AXNX have similar daily volatility (0.00).Check AXNX's competition here
ICAD vs LIVN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LIVN has a market cap of 3.4B. Regarding current trading prices, ICAD is priced at $3.87, while LIVN trades at $63.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LIVN's P/E ratio is -13.98. In terms of profitability, ICAD's ROE is -0.12%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, ICAD is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check LIVN's competition here
ICAD vs ITGR Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ITGR has a market cap of 2.9B. Regarding current trading prices, ICAD is priced at $3.87, while ITGR trades at $84.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ITGR's P/E ratio is 29.12. In terms of profitability, ICAD's ROE is -0.12%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, ICAD is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ITGR's competition here
ICAD vs NUVA Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ICAD is priced at $3.87, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ICAD's ROE is -0.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ICAD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check NUVA's competition here
ICAD vs ATEC Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, ICAD is priced at $3.87, while ATEC trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ATEC's P/E ratio is -12.89. In terms of profitability, ICAD's ROE is -0.12%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, ICAD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ATEC's competition here
ICAD vs ESTA Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, ICAD is priced at $3.87, while ESTA trades at $65.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ESTA's P/E ratio is -36.42. In terms of profitability, ICAD's ROE is -0.12%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, ICAD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ESTA's competition here
ICAD vs PMI Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PMI has a market cap of 1.8B. Regarding current trading prices, ICAD is priced at $3.87, while PMI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PMI's P/E ratio is -2.58. In terms of profitability, ICAD's ROE is -0.12%, compared to PMI's ROE of +1.64%. Regarding short-term risk, ICAD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PMI's competition here
ICAD vs TNDM Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TNDM has a market cap of 1.7B. Regarding current trading prices, ICAD is priced at $3.87, while TNDM trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TNDM's P/E ratio is -8.16. In terms of profitability, ICAD's ROE is -0.12%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, ICAD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check TNDM's competition here
ICAD vs AORT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, ICAD is priced at $3.87, while AORT trades at $36.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AORT's P/E ratio is 168.19. In terms of profitability, ICAD's ROE is -0.12%, compared to AORT's ROE of +0.02%. Regarding short-term risk, ICAD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check AORT's competition here
ICAD vs AXGN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AXGN has a market cap of 1.6B. Regarding current trading prices, ICAD is priced at $3.87, while AXGN trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AXGN's P/E ratio is -90.65. In terms of profitability, ICAD's ROE is -0.12%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, ICAD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check AXGN's competition here
ICAD vs INSP Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, ICAD is priced at $3.87, while INSP trades at $54.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INSP's P/E ratio is 10.99. In terms of profitability, ICAD's ROE is -0.12%, compared to INSP's ROE of +0.21%. Regarding short-term risk, ICAD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check INSP's competition here
ICAD vs UFPT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, ICAD is priced at $3.87, while UFPT trades at $196.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas UFPT's P/E ratio is 21.81. In terms of profitability, ICAD's ROE is -0.12%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ICAD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check UFPT's competition here
ICAD vs PRCT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, ICAD is priced at $3.87, while PRCT trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PRCT's P/E ratio is -14.99. In terms of profitability, ICAD's ROE is -0.12%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, ICAD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PRCT's competition here
ICAD vs AHCO Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87, while AHCO trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AHCO's P/E ratio is -19.07. In terms of profitability, ICAD's ROE is -0.12%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ICAD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check AHCO's competition here
ICAD vs HSKA Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ICAD's ROE is -0.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ICAD and HSKA have similar daily volatility (0.00).Check HSKA's competition here
ICAD vs IRMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87, while IRMD trades at $99.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IRMD's P/E ratio is 56.86. In terms of profitability, ICAD's ROE is -0.12%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ICAD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check IRMD's competition here
ICAD vs LMRI Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87, while LMRI trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LMRI's P/E ratio is -25.74. In terms of profitability, ICAD's ROE is -0.12%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, ICAD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check LMRI's competition here
ICAD vs SILK Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SILK's P/E ratio is -18.96. In terms of profitability, ICAD's ROE is -0.12%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ICAD is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SILK's competition here
ICAD vs CNMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87, while CNMD trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CNMD's P/E ratio is 23.83. In terms of profitability, ICAD's ROE is -0.12%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ICAD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CNMD's competition here
ICAD vs FNA Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas FNA's P/E ratio is -19.83. In terms of profitability, ICAD's ROE is -0.12%, compared to FNA's ROE of -0.17%. Regarding short-term risk, ICAD is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check FNA's competition here
ICAD vs BFLY Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, ICAD is priced at $3.87, while BFLY trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BFLY's P/E ratio is -12.81. In terms of profitability, ICAD's ROE is -0.12%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, ICAD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BFLY's competition here
ICAD vs SSII Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SSII has a market cap of 960.1M. Regarding current trading prices, ICAD is priced at $3.87, while SSII trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SSII's P/E ratio is -82.33. In terms of profitability, ICAD's ROE is -0.12%, compared to SSII's ROE of -0.30%. Regarding short-term risk, ICAD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SSII's competition here
ICAD vs INMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INMD has a market cap of 857.2M. Regarding current trading prices, ICAD is priced at $3.87, while INMD trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INMD's P/E ratio is 9.46. In terms of profitability, ICAD's ROE is -0.12%, compared to INMD's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check INMD's competition here
ICAD vs CSII Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ICAD is priced at $3.87, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CSII's P/E ratio is -20.83. In terms of profitability, ICAD's ROE is -0.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ICAD is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CSII's competition here
ICAD vs CRY Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ICAD is priced at $3.87, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CRY's P/E ratio is 425.71. In terms of profitability, ICAD's ROE is -0.12%, compared to CRY's ROE of +0.02%. Regarding short-term risk, ICAD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CRY's competition here
ICAD vs CBLL Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CBLL has a market cap of 697.5M. Regarding current trading prices, ICAD is priced at $3.87, while CBLL trades at $19.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CBLL's P/E ratio is -12.69. In terms of profitability, ICAD's ROE is -0.12%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, ICAD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CBLL's competition here
ICAD vs IART Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IART has a market cap of 696.8M. Regarding current trading prices, ICAD is priced at $3.87, while IART trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IART's P/E ratio is -1.33. In terms of profitability, ICAD's ROE is -0.12%, compared to IART's ROE of -0.44%. Regarding short-term risk, ICAD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check IART's competition here
ICAD vs SRDX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ICAD is priced at $3.87, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ICAD's ROE is -0.12%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, ICAD and SRDX have similar daily volatility (0.00).Check SRDX's competition here
ICAD vs AVNS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AVNS has a market cap of 606.6M. Regarding current trading prices, ICAD is priced at $3.87, while AVNS trades at $13.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AVNS's P/E ratio is -8.31. In terms of profitability, ICAD's ROE is -0.12%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ICAD is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check AVNS's competition here
ICAD vs TCMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TCMD has a market cap of 585.7M. Regarding current trading prices, ICAD is priced at $3.87, while TCMD trades at $27.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TCMD's P/E ratio is 31.83. In terms of profitability, ICAD's ROE is -0.12%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, ICAD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check TCMD's competition here
ICAD vs BVS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BVS has a market cap of 582.7M. Regarding current trading prices, ICAD is priced at $3.87, while BVS trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BVS's P/E ratio is 26.21. In terms of profitability, ICAD's ROE is -0.12%, compared to BVS's ROE of +0.14%. Regarding short-term risk, ICAD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BVS's competition here
ICAD vs APEN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ICAD is priced at $3.87, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas APEN's P/E ratio is -9.43. In terms of profitability, ICAD's ROE is -0.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ICAD is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check APEN's competition here
ICAD vs CTKB Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CTKB has a market cap of 577.2M. Regarding current trading prices, ICAD is priced at $3.87, while CTKB trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CTKB's P/E ratio is -8.63. In terms of profitability, ICAD's ROE is -0.12%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, ICAD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CTKB's competition here
ICAD vs SIBN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SIBN has a market cap of 564.9M. Regarding current trading prices, ICAD is priced at $3.87, while SIBN trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SIBN's P/E ratio is -29.07. In terms of profitability, ICAD's ROE is -0.12%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, ICAD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SIBN's competition here
ICAD vs BWAY Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BWAY has a market cap of 535.8M. Regarding current trading prices, ICAD is priced at $3.87, while BWAY trades at $13.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BWAY's P/E ratio is 75.89. In terms of profitability, ICAD's ROE is -0.12%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BWAY's competition here
ICAD vs ZIMV Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ICAD is priced at $3.87, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ICAD's ROE is -0.12%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, ICAD and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here
ICAD vs OFIX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, OFIX has a market cap of 467.7M. Regarding current trading prices, ICAD is priced at $3.87, while OFIX trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas OFIX's P/E ratio is -5.00. In terms of profitability, ICAD's ROE is -0.12%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, ICAD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check OFIX's competition here
ICAD vs VREX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, VREX has a market cap of 446.9M. Regarding current trading prices, ICAD is priced at $3.87, while VREX trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas VREX's P/E ratio is -6.50. In terms of profitability, ICAD's ROE is -0.12%, compared to VREX's ROE of -0.14%. Regarding short-term risk, ICAD is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check VREX's competition here
ICAD vs NPCE Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NPCE has a market cap of 437.7M. Regarding current trading prices, ICAD is priced at $3.87, while NPCE trades at $13.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NPCE's P/E ratio is -19.70. In terms of profitability, ICAD's ROE is -0.12%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, ICAD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check NPCE's competition here
ICAD vs KIDS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, KIDS has a market cap of 417.6M. Regarding current trading prices, ICAD is priced at $3.87, while KIDS trades at $16.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas KIDS's P/E ratio is -9.78. In terms of profitability, ICAD's ROE is -0.12%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ICAD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check KIDS's competition here
ICAD vs PACB Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PACB has a market cap of 401.7M. Regarding current trading prices, ICAD is priced at $3.87, while PACB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PACB's P/E ratio is -0.73. In terms of profitability, ICAD's ROE is -0.12%, compared to PACB's ROE of -11.23%. Regarding short-term risk, ICAD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PACB's competition here
ICAD vs LAB Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LAB has a market cap of 378.6M. Regarding current trading prices, ICAD is priced at $3.87, while LAB trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LAB's P/E ratio is -6.56. In terms of profitability, ICAD's ROE is -0.12%, compared to LAB's ROE of -0.18%. Regarding short-term risk, ICAD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check LAB's competition here
ICAD vs VMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, VMD has a market cap of 336.2M. Regarding current trading prices, ICAD is priced at $3.87, while VMD trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas VMD's P/E ratio is 23.54. In terms of profitability, ICAD's ROE is -0.12%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check VMD's competition here
ICAD vs CERS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CERS has a market cap of 329.6M. Regarding current trading prices, ICAD is priced at $3.87, while CERS trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CERS's P/E ratio is -21.44. In terms of profitability, ICAD's ROE is -0.12%, compared to CERS's ROE of -0.26%. Regarding short-term risk, ICAD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CERS's competition here
ICAD vs CATX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CATX has a market cap of 327.4M. Regarding current trading prices, ICAD is priced at $3.87, while CATX trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CATX's P/E ratio is -2.94. In terms of profitability, ICAD's ROE is -0.12%, compared to CATX's ROE of -0.41%. Regarding short-term risk, ICAD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CATX's competition here
ICAD vs DCTH Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, DCTH has a market cap of 315.1M. Regarding current trading prices, ICAD is priced at $3.87, while DCTH trades at $9.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas DCTH's P/E ratio is 129.57. In terms of profitability, ICAD's ROE is -0.12%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, ICAD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check DCTH's competition here
ICAD vs SMLR Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ICAD is priced at $3.87, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ICAD's ROE is -0.12%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ICAD and SMLR have similar daily volatility (0.00).Check SMLR's competition here
ICAD vs SENS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SENS has a market cap of 270.7M. Regarding current trading prices, ICAD is priced at $3.87, while SENS trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SENS's P/E ratio is -3.90. In terms of profitability, ICAD's ROE is -0.12%, compared to SENS's ROE of -1.04%. Regarding short-term risk, ICAD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SENS's competition here
ICAD vs CLPT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CLPT has a market cap of 268.3M. Regarding current trading prices, ICAD is priced at $3.87, while CLPT trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CLPT's P/E ratio is -10.87. In terms of profitability, ICAD's ROE is -0.12%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, ICAD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CLPT's competition here
ICAD vs RXST Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, RXST has a market cap of 265.8M. Regarding current trading prices, ICAD is priced at $3.87, while RXST trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas RXST's P/E ratio is -6.78. In terms of profitability, ICAD's ROE is -0.12%, compared to RXST's ROE of -0.14%. Regarding short-term risk, ICAD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check RXST's competition here
ICAD vs MGRM Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ICAD is priced at $3.87, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ICAD's ROE is -0.12%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, ICAD and MGRM have similar daily volatility (0.00).Check MGRM's competition here
ICAD vs MASS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MASS has a market cap of 228.4M. Regarding current trading prices, ICAD is priced at $3.87, while MASS trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MASS's P/E ratio is -6.57. In terms of profitability, ICAD's ROE is -0.12%, compared to MASS's ROE of +0.13%. Regarding short-term risk, ICAD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check MASS's competition here
ICAD vs CVRX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CVRX has a market cap of 228.1M. Regarding current trading prices, ICAD is priced at $3.87, while CVRX trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CVRX's P/E ratio is -4.25. In terms of profitability, ICAD's ROE is -0.12%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, ICAD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check CVRX's competition here
ICAD vs NVRO Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ICAD is priced at $3.87, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ICAD's ROE is -0.12%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, ICAD is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check NVRO's competition here
ICAD vs EYES Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ICAD is priced at $3.87, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas EYES's P/E ratio is N/A. In terms of profitability, ICAD's ROE is -0.12%, compared to EYES's ROE of -4.16%. Regarding short-term risk, ICAD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check EYES's competition here
ICAD vs AVR Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AVR has a market cap of 206.4M. Regarding current trading prices, ICAD is priced at $3.87, while AVR trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AVR's P/E ratio is -2.20. In terms of profitability, ICAD's ROE is -0.12%, compared to AVR's ROE of -5.28%. Regarding short-term risk, ICAD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check AVR's competition here
ICAD vs QTRX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QTRX has a market cap of 200.9M. Regarding current trading prices, ICAD is priced at $3.87, while QTRX trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QTRX's P/E ratio is -1.71. In terms of profitability, ICAD's ROE is -0.12%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ICAD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check QTRX's competition here
ICAD vs ANIK Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ANIK has a market cap of 199.8M. Regarding current trading prices, ICAD is priced at $3.87, while ANIK trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ANIK's P/E ratio is -19.79. In terms of profitability, ICAD's ROE is -0.12%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, ICAD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ANIK's competition here
ICAD vs ELMD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ELMD has a market cap of 192.7M. Regarding current trading prices, ICAD is priced at $3.87, while ELMD trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ELMD's P/E ratio is 22.44. In terms of profitability, ICAD's ROE is -0.12%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, ICAD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check ELMD's competition here
ICAD vs BSGM Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ICAD is priced at $3.87, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ICAD's ROE is -0.12%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ICAD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check BSGM's competition here
ICAD vs QTI Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QTI has a market cap of 188.6M. Regarding current trading prices, ICAD is priced at $3.87, while QTI trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QTI's P/E ratio is -3.46. In terms of profitability, ICAD's ROE is -0.12%, compared to QTI's ROE of +3.64%. Regarding short-term risk, ICAD is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check QTI's competition here
ICAD vs SGHT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SGHT has a market cap of 187.4M. Regarding current trading prices, ICAD is priced at $3.87, while SGHT trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SGHT's P/E ratio is -4.69. In terms of profitability, ICAD's ROE is -0.12%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, ICAD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SGHT's competition here
ICAD vs MDGS Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ICAD is priced at $3.87, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ICAD's ROE is -0.12%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ICAD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check MDGS's competition here
ICAD vs SNWV Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SNWV has a market cap of 173.2M. Regarding current trading prices, ICAD is priced at $3.87, while SNWV trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SNWV's P/E ratio is -27.67. In terms of profitability, ICAD's ROE is -0.12%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, ICAD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check SNWV's competition here
ICAD vs INGN Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INGN has a market cap of 166.1M. Regarding current trading prices, ICAD is priced at $3.87, while INGN trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INGN's P/E ratio is -7.09. In terms of profitability, ICAD's ROE is -0.12%, compared to INGN's ROE of -0.12%. Regarding short-term risk, ICAD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check INGN's competition here
ICAD vs QIPT Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ICAD is priced at $3.87, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ICAD's ROE is -0.12%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ICAD and QIPT have similar daily volatility (0.00).Check QIPT's competition here
ICAD vs NNOX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, ICAD is priced at $3.87, while NNOX trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NNOX's P/E ratio is -2.74. In terms of profitability, ICAD's ROE is -0.12%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, ICAD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check NNOX's competition here
ICAD vs PROF Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PROF has a market cap of 153.1M. Regarding current trading prices, ICAD is priced at $3.87, while PROF trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PROF's P/E ratio is -3.59. In terms of profitability, ICAD's ROE is -0.12%, compared to PROF's ROE of -0.80%. Regarding short-term risk, ICAD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check PROF's competition here
ICAD vs TLSI Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TLSI has a market cap of 149M. Regarding current trading prices, ICAD is priced at $3.87, while TLSI trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TLSI's P/E ratio is -2.14. In terms of profitability, ICAD's ROE is -0.12%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, ICAD is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check TLSI's competition here
ICAD vs APYX Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, APYX has a market cap of 144.3M. Regarding current trading prices, ICAD is priced at $3.87, while APYX trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas APYX's P/E ratio is -12.78. In terms of profitability, ICAD's ROE is -0.12%, compared to APYX's ROE of -1.18%. Regarding short-term risk, ICAD is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check APYX's competition here
ICAD vs EDAP Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, EDAP has a market cap of 135.7M. Regarding current trading prices, ICAD is priced at $3.87, while EDAP trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas EDAP's P/E ratio is -6.60. In terms of profitability, ICAD's ROE is -0.12%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, ICAD is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check EDAP's competition here
ICAD vs LUCD Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LUCD has a market cap of 127.2M. Regarding current trading prices, ICAD is priced at $3.87, while LUCD trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LUCD's P/E ratio is -1.62. In terms of profitability, ICAD's ROE is -0.12%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, ICAD is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check LUCD's competition here
ICAD vs FONR Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, FONR has a market cap of 113.4M. Regarding current trading prices, ICAD is priced at $3.87, while FONR trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas FONR's P/E ratio is 15.98. In terms of profitability, ICAD's ROE is -0.12%, compared to FONR's ROE of +0.04%. Regarding short-term risk, ICAD is less volatile compared to FONR. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check FONR's competition here
ICAD vs RPID Comparison March 2026
ICAD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, RPID has a market cap of 104.2M. Regarding current trading prices, ICAD is priced at $3.87, while RPID trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas RPID's P/E ratio is -2.35. In terms of profitability, ICAD's ROE is -0.12%, compared to RPID's ROE of -0.95%. Regarding short-term risk, ICAD is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ICAD.Check RPID's competition here